Wayne Koff
25Patents
5h-index
29Co-inventors
69Inventor score
Filing activity: Oct 26, 2000 → Jun 5, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9464131B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 14 | Active |
| US9051362B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 14 | Active |
| US10087239B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 12 | Active |
| US6531313B1 | Invasive bacterial vectors for expressing alphavirus replicons | Emerging Cross-Sectional Technologies | 12 | Expired |
| US8586056B2 | HIV-1 envelope glycoprotein | Chemistry; Metallurgy | 11 | Active |
| US10093720B2 | Broadly neutralizing antibody and uses thereof | Chemistry; Metallurgy | 4 | Active |
| US11319362B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| USRE49037E1 | Broadly neutralizing antibody and uses thereof | General | 1 | Active |
| US12312396B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10894080B2 | Transgenic VERO-CD4/CCR5 cell line | Chemistry; Metallurgy | 0 | Active |
| US9796774B2 | HIV-1 broadly neutralizing antibodies | Chemistry; Metallurgy | 0 | Active |
| US9925258B2 | Replication-competent VSV-HIV Env vaccines | Chemistry; Metallurgy | 0 | Active |
| US12018067B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10239934B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11845789B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US8105600B2 | Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env | Chemistry; Metallurgy | 0 | Active |
| US10279027B2 | Transgenic Vero-CD4/CCR5 cell line | Chemistry; Metallurgy | 0 | Active |
| US10836811B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 0 | Active |
| USRE50268E1 | Broadly neutralizing antibody and uses thereof | General | 0 | Active |
| US10865234B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11584789B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US9382311B2 | HIV-1 broadly neutralizing antibodies | Chemistry; Metallurgy | 0 | Active |
| US9920111B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10407493B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12410243B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.